Table 2

Description of the subgroup of VTE cases and non-cases regarding parameters considered in this study as potential VTE risk factors at baseline of the observation period 1993 – 2003 Only definite and probable VTEs were considered as cases in this table, i.e. possible & potential VTE were excluded. Definitions of variables see text.

Non-cases

VTE cases

Total cohort

N

n (%)

N

n (%)

N

n (%)

Demographic data

Age*: 30+ years

4286

1456 (34.0)

34

21 (61.8)

4320

1477 (34.2)

BMI*: 25+

4275

1076 (25.2)

34

15 (44.1)

4309

1091 (25.3)

OC use: yes, ever

4285

3941 (92.0)

34

32 (94.1)

4319

3973 (92.0)

Other hormones: yes, ever

4267

267 (6.3)

34

3 (8.8)

4301

270 (6.3)

Smoking: yes, ever

4284

2278 (53.2)

34

18 (52.9)

4318

2296 (53.2)

Medical history

Personal history of VTE*: yes

4286

37 (0.9)

34

4 (11.8)

4320

41 (1.0)

Family history of VTE*: yes

4286

470 (11.0)

34

10 (29.4)

4320

480 (11.1)

Family history of varicose veins*: yes

4286

1902 (44.4)

34

23 (67.7)

4320

1925 (44.6)

Family history of MI*: yes

4286

482 (11.3)

34

8 (23.5)

4320

490 (11.3)

Family history of stroke: yes

4286

302 (7.1)

34

5 (14.7)

4320

307 (7.1)

Laboratory & genetic markers

FVL mutation^§: yes

4273

267 (6.3)

33

4 (12.1)

4306

271 (6.3)

Prothrombin mutation^§: yes

4199

140 (3.3)

31

2 (6.5)

4230

142 (3.4)

Protein C deficiency ^#: yes

4281

4087 (95.5)

34

30 (88.2)

4315

4117 (95.4)

AT deficiency ^#: yes

4282

4073 (95.1)

34

33 (97.1)

4316

4106 (95.1)

MTHFR^§: yes

4199

2415 (57.5)

31

17 (54.8)

4230

2432 (57.5)

^§ homo- and heterozygote together

* significant difference between VTE cases and non-cases (p < 0.05)

^# definition see methods

Spannagl et al. Thrombosis Journal 2005 3:8   doi:10.1186/1477-9560-3-8